Article Text

Download PDFPDF
Visceral fat and bevacizumab in metastatic colorectal cancer
  1. A M Jubb
  1. Nuffield Department of Clinical Laboratory Sciences, University of Oxford, Oxford, UK
  1. Correspondence to Dr Adrian M. Jubb, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK; adrian.jubb{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The addition of bevacizumab (a monoclonal antibody against vascular endothelial growth factor, VEGF) to 5-fluorouracil-based chemotherapy has a proven overall survival benefit in metastatic colorectal cancer. Nevertheless, the cost of antibody therapies and increasing evidence that the efficacy of targeted agents may be predicted by patient and tumour characteristics have prompted the investigation of biomarkers that may predict benefit from bevacizumab. Guiu et al examined the impact of body mass index, visceral fat area and subcutaneous fat area on the clinical outcome of patients with metastatic colorectal cancer treated with chemotherapy alone or chemotherapy plus bevacizumab. …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Linked Articles

  • PostScript
    F Bonnetain B Guiu F Ghiringhelli